AcelRx Pharma Posts Narrower Loss In Q3; To Acquire Lowell Therapeutics

AcelRx Pharmaceuticals, Inc. (ACRX) reported a third-quarter loss per share of $0.07 compared to a loss of $0.10, prior year. Analysts polled by Thomson Reuters expected the company to report a loss per share of $0.07, for the quarter. Analysts' estimates typically exclude special items. Net loss was $8.4 million compared to a loss of $8.9 million.

Revenue increased to $1.86 million from $1.37 million, a year ago. Analysts on average had estimated $1.9 million in revenue.

Separately, AcelRx Pharmaceuticals announced the execution of a definitive merger agreement to acquire Lowell Therapeutics, Inc. Lowell is a privately held company developing Niyad, a regional anticoagulant for the dialysis circuit during continuous renal replacement therapy for acute kidney injury patients.

The deal is valued at approximately $32.5 million plus net cash acquired and certain other adjustments, and includes approximately $26.0 million of contingent consideration. An amount of shares of AcelRx common stock valued at approximately $6.5 million is anticipated to be issued to Lowell securityholders at the closing.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Covid vaccine makers Pfizer Inc. and BioNTech SE announced a new $3.2 billion vaccine supply deal with the U.S. Government, as the country is bracing for a Covid outbreak this fall. Under the deal, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg) of Pfizer -BioNTech covid vaccines initially. The order may include adult Omicron-adapted COVID-19 vaccines. Samsung Electronics Co. has started the initial mass production of 3-nanometer or nm chips, which is considered as the most advanced chip in the world. In its move, the South Korean tech major beats rival Taiwan Semiconductor Manufacturing Co., the world's largest chip manufacturer, which is reportedly in the process to build one. Bryant Ranch Prepack Inc. is recalling certain Morphine Sulfate Extended-Release Tablets citing incorrect labeling, the U.S. Food and Drug Administration said. The recall involves one lot of Morphine Sulfate 30 mg Extended-Release tablets, and one lot of Morphine Sulfate 60 mg Extended-Release tablets to the consumer level.
Follow RTT